Mitigate (ATD)
Abstract
The Mitigate Advanced Technology Development (ATD) Project provides the Joint Force the ability to preserve combat power by mitigating exposure to chemical and biological (CB) hazards and restoring combat readiness of critical personnel and platforms. Thrust Areas included in this Project are: (1) Enhanced Survivability Coatings (2) Equipment Decontamination (3) Multifunctional Materials for Protection (4) Personnel Decontamination (5) Biological Warfare Defense Therapeutics (6) Discovery of Medical Countermeasures Against New and Emerging (DOMANE) (7) Nerve Agent Prophylaxis/Pretreatments (8) Pharmaceutical Based Agents (PBAs) (9) Reactivators of Acetylcholinesterase as Therapeutics (ReACT) Enhanced Survivability Coatings: Addresses military equipment coating ease of decontamination and resistance to chemical agent penetration. Projects will develop temporary coatings that resist chemical agent absorption and are quickly decontaminated in the field and allow the rapid regeneration of combat power. Equipment Decontamination: Develops decontaminant formulations and procedures that reduce or eliminate residual contamination hazards; enables unit-level decontamination with rapid unmasking; reduces logistic needs, enables rapid sorting of clean from dirty to return high-value equipment to normal use, and develops improved realistic test methods. Efforts address the capability to decontaminate personal equipment. The FY23 efforts include additional investments in enhanced biodefense and pandemic preparedness. Multifunctional Materials for Protection: Discovers, develops and integrates novel, reactive/catalytic materials and scale material manufacturing with maximum sorption and reactivity, and characterize materials using state-of-the-art in operando and ambient pressure spectroscopies, for eventual integration into next generation decontaminants that reactively decontaminate chemical warfare agents. Personnel Decontamination: Develops decontaminants with lower lifecycle costs and storage constraints and determine of time, efficacy and logistics burdens to Warfighters for mass casualty decontamination, including possible substitutions for current approved personnel decontamination formulations. Biological Warfare Defense Therapeutics: Develops broad-spectrum bacterial, toxin and viral therapeutics, and label expansion (repurposing) of medical countermeasures that are Food and Drug Administration (FDA) approved or in advanced stages of clinical development. These efforts are coordinated with Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA), and across the interagency and Department, to leverage public and force/defense health related investments made to minimize risk and speed approval of novel antibiotic countermeasures. The FY23 efforts include additional investments in enhanced biodefense and pandemic preparedness. Discovery of Medical Countermeasures Against New and Emerging (DOMANE): Provides innovative and rapid medical countermeasures (MCMs) development capabilities that reduce developmental risks, cost and schedule associated with MCM fielding, and afford protection against and allow the Joint Force to rapidly respond to traditional, new and emerging biological warfare threat exposures to allow freedom of action. The FY23 efforts include additional investments in enhanced biodefense and pandemic preparedness. Nerve Agent Prophylaxis/Pretreatments: Develops and transitions novel products and information to address current and emerging chemical threats to protect the lives and effectiveness of Warfighters, thus maintaining force strength and force capability. FY23 focuses on obtaining the first prophylactic MCMs designed to prevent severe morbidity and mortality upon exposure to nerve agents without the need for additional individual physical protective equipment. Pharmaceutical Based Agents (PBA): Assesses candidate MCMs and transitioning them to partner US Government entities for development into fieldable drug products. Activities advancing therapeutic drugs for protection against opioid agents and developing MCMs to treat non-opioid sedatives in preparation for Phase 1 or other relevant clinical trials. Reactivators of Acetylcholinesterase as Therapeutics (ReACT): Develops broad-spectrum, centrally-acting acetylcholinesterase reactivators that increase survival, reduce morbidity, and decrease neurological damage.
Document Details
- Document Type
- Project
- Publication Date
- Oct 01, 2023
- Source ID
- MT3_0603384BP_3_0400_PB_2023
Related Documents
- Root: CHEMICAL/BIOLOGICAL DEFENSE (ATD)
- Child Accomplishment: 1) Multifunctional Materials for Protection
- Child Accomplishment: 2) Enhanced Survivability Coatings
- Child Accomplishment: 3) Equipment Decontamination
- Child Accomplishment: 4) Equipment Decontamination - Enhanced Biodefense (ENBD)
- Child Accomplishment: 5) Personnel Decontamination
- Child Accomplishment: 6) Biological Warfare Defense Therapeutics
- Child Accomplishment: 7) Biological Warfare Defense Therapeutics - Enhanced Biodefense (ENBD)
- Child Accomplishment: 8) Discovery of Medical Countermeasures Against New and Emerging (DOMANE)
- Child Accomplishment: 9) Discovery of Medical Countermeasures Against New and Emerging (DOMANE) - Enhanced Biodefense (ENBD)
- Child Accomplishment: 10) Nerve Agent Prophylaxis/Pretreatments
- Child Accomplishment: 11) Pharmaceutical Based Agents (PBAs)
- Child Accomplishment: 12) Reactivators of AChE as Therapeutics (ReACT)